biocon.com › docs › PressRelease9m2018.pdf · Biocon launches KRABEVA@ a biosimilar Bevacizumab...

5

Transcript of biocon.com › docs › PressRelease9m2018.pdf · Biocon launches KRABEVA@ a biosimilar Bevacizumab...

Page 1: biocon.com › docs › PressRelease9m2018.pdf · Biocon launches KRABEVA@ a biosimilar Bevacizumab in India, for the treatment of patients with metastatic colorectal cancer and other
Page 2: biocon.com › docs › PressRelease9m2018.pdf · Biocon launches KRABEVA@ a biosimilar Bevacizumab in India, for the treatment of patients with metastatic colorectal cancer and other
Page 3: biocon.com › docs › PressRelease9m2018.pdf · Biocon launches KRABEVA@ a biosimilar Bevacizumab in India, for the treatment of patients with metastatic colorectal cancer and other
Page 4: biocon.com › docs › PressRelease9m2018.pdf · Biocon launches KRABEVA@ a biosimilar Bevacizumab in India, for the treatment of patients with metastatic colorectal cancer and other
Page 5: biocon.com › docs › PressRelease9m2018.pdf · Biocon launches KRABEVA@ a biosimilar Bevacizumab in India, for the treatment of patients with metastatic colorectal cancer and other

Biocon Share Price

Biocon Share Price

Biocon ltd

Biocon ltd

Chemotherapy plus or minus bevacizumab for platinum ......Chemotherapy plus or minus bevacizumab for platinum-sensitive ovarian cancer patients recurring after a bevacizumab containing

Chemotherapy plus or minus bevacizumab for platinum ......Chemotherapy plus or minus bevacizumab for platinum-sensitive ovarian cancer patients recurring after a bevacizumab containing

Biocon - stock analysis

Biocon - stock analysis

Biocon FY2014 Results

Biocon FY2014 Results

Biocon Cre To

Biocon Cre To

Biocon AR2011

Biocon AR2011

Biocon Investor Presentation_March_2012_9M

Biocon Investor Presentation_March_2012_9M

BIOCON- HRD

BIOCON- HRD

biocon ivmp

biocon ivmp

Biocon Vikash presentation

Biocon Vikash presentation

Biocon Group Ppt

Biocon Group Ppt

Biocon final

Biocon final

KRABEVA LEAFLET - Biocon

KRABEVA LEAFLET - Biocon

Biocon Case

Biocon Case

biocon stm

biocon stm

Biocon Case Study

Biocon Case Study

MFOLFOX-bevacizumab or XELOX- bevacizumab then bevacizumab alone or with erlotinib in 1st line treatment of patients with metastatic colorectal cancer.

MFOLFOX-bevacizumab or XELOX- bevacizumab then bevacizumab alone or with erlotinib in 1st line treatment of patients with metastatic colorectal cancer.

Bevacizumab Beyond Progression ?

Bevacizumab Beyond Progression ?

Biocon final AR21

Biocon final AR21